Neil Bhowmick - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
Chief Scientific Officer
Signature
/s/ Neil Bhowmick
Issuer symbol
KAPA
Transactions as of
08 Oct 2025
Net transactions value
$0
Form type
4
Filing time
30 Dec 2025, 16:10:14 UTC
Previous filing
07 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bhowmick Neil Chief Scientific Officer C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES /s/ Neil Bhowmick 30 Dec 2025 0001872210

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +171,756 +15% $0.000000 1,311,739 08 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026.
F2 Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting.